Discovering Novel Retinal Vascular Models to Translate Neovascularization Targets Beyond Anti-VEGF into the Clinic

The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit returned to Boston this March to unite 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the only industry-dedicated forum to transform the potential of treatment of chronic, sight-threatening retinal vascular diseases to improve patient outcomes.     

Attendees joined the most comprehensive Wet AMD & Diabetic Eye Disease forum to: 

• Hear data-driven case studies from industry experts from the likes of Bayer, Boehringer Ingelheim, Novartis and Genentech
• Participate with the interactive expert panel discussion navigating the current anti-VEGF treatment
• Meet and network with industry-based retinal vascular preclinical and clinical R&D scientists from Annexin Pharmaceuticals, OcuTerra Therapeutics, University of Southern California, Kodiak Sciences and more